Holen Sie sich die Stockscreener-App
6.81
3.54%
-0.25
Handel nachbörslich:
6.94
0.13
+1.91%
Schlusskurs vom Vortag:
$7.06
Offen:
$7.05
24-Stunden-Volumen:
61,297
Relative Volume:
0.80
Marktkapitalisierung:
$656.03M
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
72.83
EPS:
0.0935
Netto-Cashflow:
$6.37M
1W Leistung:
-6.20%
1M Leistung:
-10.16%
6M Leistung:
-12.69%
1J Leistung:
-43.25%
1-Tages-Spanne:
$6.76
$7.055
1-Wochen-Bereich:
$6.76
$7.265
52-Wochen-Spanne:
$6.11
$13.75
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
(858) 567-7770
Adresse
12770 HIGH BLUFF DRIVE, SAN DIEGO
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.81 | 680.11M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Jefferies | Buy |
| 2025-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Given Average Rating of "Hold" by Analysts - MarketBeat
Gyre Therapeutics president sells $45,380 in stock - MSN
Undiscovered Gems in the US Market to Explore This December 2025 - Yahoo Finance
Published on: 2025-12-21 18:19:37 - Улправда
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6% – Time to Sell? - Defense World
Will Gyre Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Breakouts & Low Drawdown Investment Strategies - Улправда
Gyre Therapeutics Earnings Notes - Trefis
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.6%Time to Sell? - MarketBeat
Why Gyre Therapeutics Inc. stock remains on buy lists2025 Trading Recap & Long-Term Capital Growth Strategies - Улправда
Levels Update: Is Gyre Therapeutics Inc. stock vulnerable to regulatory risks2025 Major Catalysts & Weekly Momentum Picks - Улправда
Will Gyre Therapeutics Inc. stock deliver consistent dividends2025 Market WrapUp & Reliable Price Action Trade Plans - Улправда
Does Gyre Therapeutics Inc. stock trade at a discount to peers2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
US High Growth Tech Stocks to Watch - Yahoo Finance
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 5.9%Should You Sell? - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages - Defense World
GNI Group’s Subsidiary Completes Enrollment for Key Clinical Trial - MSN
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 2.3%Time to Buy? - MarketBeat
Gyre Therapeutics (GYRE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Gyre Therapeutics Stock Built to Withstand a Pullback? - Trefis
Regarding video postings related to our company group information on some social networking services (SNS). - 富途牛牛
Published on: 2025-11-27 08:38:09 - moha.gov.vn
Is Gyre Therapeutics Inc a good long term investmentMarket Depth Overview & Free Unmatched Market Performance - earlytimes.in
Is Gyre Therapeutics Inc. stock a dividend growth opportunity2025 Short Interest & Real-Time Volume Triggers - newser.com
Is Gyre Therapeutics Inc. stock dividend yield sustainableJuly 2025 Closing Moves & Safe Entry Point Identification - newser.com
What drives Gyre Therapeutics Inc stock priceMarket Capitalization Trends & Free Triple Digit Wealth Increase - earlytimes.in
Will Gyre Therapeutics Inc. stock return to pre crisis levelsLong Setup & Low Risk High Win Rate Picks - newser.com
Should I hold or sell Gyre Therapeutics Inc. stock in 2025July 2025 Final Week & Verified Technical Signals - newser.com
Why Gyre Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Weekly Chart Analysis and Guides - newser.com
What recovery options are there for Gyre Therapeutics Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Can Gyre Therapeutics Inc. stock sustain institutional interest2025 Biggest Moves & Smart Money Movement Tracker - newser.com
How Gyre Therapeutics Inc. stock performs in interest rate cyclesMarket Activity Recap & Daily Volume Surge Signals - newser.com
Is Gyre Therapeutics Inc. stock entering bullish territoryTrade Entry Summary & Long-Term Safe Investment Ideas - newser.com
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):